[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Au WY: Current management of nasal NK/T-cell lymphoma. Oncology (Williston Park); 2010 Apr 15;24(4):352-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of nasal NK/T-cell lymphoma.
  • Nasal natural killer (NK)/T-cell lymphoma--classified as extranodal NK/T-cell lymphoma (ENKTL), nasal type, by the World Health Organization--is a non-Hodgkin lymphoma that is almost always associated with Epstein-Barr virus.
  • Up to 75% of ENKTL cases occur in the upper aerodigestive tract, primarily the nasal cavity.
  • It is the most common type of peripheral T-cell lymphoma in many Asian countries.
  • Histologic diagnosis is essential, and staging consists of bilateral bone marrow biopsy and imaging of the neck, thorax, abdomen, and pelvis.
  • There is a marked dichotomy in treatment and survival between localized and disseminated disease.
  • Since disease incidence is rare even in prevalent areas, experience is limited and most treatment protocols are consensus-guided.
  • Early-stage, localized nasal disease is highly curable with combination therapy, but the optimal dose, combination, and sequence of radiotherapy and chemotherapy are still undefined.
  • For disseminated and refractory cases, the 5-year survival rate is below 10%, and better methods of treatment are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Extranodal NK-T-Cell / therapy. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Middle Aged. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2010 Apr 15;24(4):362-3 [20464849.001]
  • [CommentIn] Oncology (Williston Park). 2010 Apr 15;24(4):359, 362 [20464848.001]
  • (PMID = 20464847.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Toba A, Tamura Y, Osajima Y, Kinbara Y, Sato M, Yamaga R, Hashimoto R, Mori S, Miyakoshi S, Ota M, Ito H, Araki A: [A case of nasal NK/T cell lymphoma presenting with bilateral giant adrenal tumors]. Nihon Ronen Igakkai Zasshi; 2008 Nov;45(6):660-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of nasal NK/T cell lymphoma presenting with bilateral giant adrenal tumors].
  • A tumor was also found inside nasal cavity by enhanced computed tomography (CT), and abnormal uptake in the nasal cavity and adrenal gland was shown in gallium scintigraphy.
  • Biopsy of the nasal tumor revealed nasal natural killer or thymus-derived (NK/T) cell lymphoma.
  • No Epstein-Barr virus (EBV) -encoded RNA was detected in tissue.
  • After THP-COP chemotherapy regimen, both the nasal and adrenal tumors decreased in size.
  • After treatment with heparin and warfarin, emboli disappeared.
  • Chemotherapy was continued, but perforation of the small intestine occurred.
  • In addition, since her cortisol circadian rhythm was lost and cortisol levels were not completely suppressed by the 1 mg and 8 mg dexamethasone test, she met the criteria of the diagnosis of preclinical Cushing syndrome.
  • NK/T cell lymphoma with giant adrenal tumor is extremely rare, but should be considered as one of the differential diagnoses of bilateral adrenal tumor.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Lymphoma, Extranodal NK-T-Cell / complications. Nose Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179800.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Rhee KH, Hong SC, An JM, Huh J, Sook RJ, Lee JS, Suh C: Mediastinal single nodal relapse of a nasal NK/T cell lymphoma. Korean J Intern Med; 2007 Sep;22(3):201-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal single nodal relapse of a nasal NK/T cell lymphoma.
  • A nasal NK/T cell lymphoma is a very aggressive form of lymphoma.
  • Patterns of relapse after treatment have not been systematically evaluated, and mediastinal nodal relapse at a primary site has never been documented.
  • We describe here a 40-year old man who presented with a nasal obstruction caused by a protruding mass that was identified as a nasal NK/T cell lymphoma.
  • The initial work-up, including chest and abdominopelvic computed tomography (CT) and positron emission tomography (PET), showed no regional or distant metastasis.
  • A CT scan performed following three cycles of chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) showed that the mass had nearly disappeared.
  • Radiation therapy undertaken following chemotherapy was given to the primary site.
  • However, PET performed following radiotherapy revealed a single mediastinal lymphadenopathy, with no evidence of residual tumor in the nasal cavity.
  • A biopsy using video-assisted thoracoscopy (VATS) showed the presence of a recurrent NK/T cell lymphoma with an immunophenotype identical to that of the primary nasal lymphoma.
  • An additional three cycles of CHOP chemotherapy were administered, and the patient remains alive, with no evidence of disease 30 months after the initial relapse.
  • These findings indicate that early detection with PET and prompt surgical excision with the use of VATS can lead to successful treatment of a relapsed nasal NK/T cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Lymphatic Metastasis. Male. Positron-Emission Tomography. Prednisolone / administration & dosage. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jan;18(1):54-63 [10623693.001]
  • [Cites] Ai Zheng. 2006 Apr;25(4):465-70 [16613682.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1091-7 [12173024.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1197-202 [14654477.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):1063-8 [14674081.001]
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] Histopathology. 2004 May;44(5):480-9 [15139996.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):940-6 [3373265.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1832-7 [3199167.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):268-79 [1996731.001]
  • [Cites] Acta Oncol. 1993;32(1):69-72 [8466767.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):666-70 [7884427.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]
  • [Cites] Jpn J Clin Oncol. 2005 Jan;35(1):1-5 [15681596.001]
  • [Cites] Nucl Med Commun. 2005 Nov;26(11):989-94 [16208177.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):181-9 [16382127.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] AJR Am J Roentgenol. 2000 Apr;174(4):1141-5 [10749267.001]
  • (PMID = 17939339.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Other-IDs] NLM/ PMC2687701
  •  go-up   go-down


Advertisement
4. Lee EJ, Kim TW, Heo JW, Yu HG, Chung H: Natural killer/T-cell lymphoma of nasal type with intraocular involvement: case report. Eur J Ophthalmol; 2010 Jan-Feb;20(1):215-7
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer/T-cell lymphoma of nasal type with intraocular involvement: case report.
  • PURPOSE: To report an unusual presentation of disseminated, intraocular, extranodal natural killer/T-cell lymphoma, nasal type (NK/T-cell lymphoma), originating from nasal NK/T-cell lymphoma.
  • RESULTS: A 63-year-old woman who had been treated with systemic chemotherapy and radiotherapy for NK/T-cell lymphoma in the nasal cavity presented with vitreous haze of the right eye.
  • Despite anti-inflammatory therapy, the right eye showed poor clinical response and received diagnostic vitrectomy.
  • The vitreous specimen contained many large, pleomorphic lymphoma cells.
  • A diagnosis of T-cell lymphoma in the vitreous was made; the tumor likely originated from nasal NK/T-cell lymphoma.
  • The patient was treated with intrathecal chemotherapy and intravitreal methotrexate injection.
  • CONCLUSIONS: Vitreous infiltration without uveoretinal involvement can be an unusual manifestation of intraocular NK/T-cell lymphoma.
  • Clinician awareness of possible ocular involvement may assist in the diagnosis of disseminated NK/T-cell lymphoma.
  • [MeSH-major] Eye Neoplasms / pathology. Killer Cells, Natural. Lymphoma, T-Cell / pathology. Nose Neoplasms / pathology. Vitreous Body / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Injections, Spinal. Middle Aged. Neoplasm Invasiveness. Vitrectomy

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882515.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Mendenhall WM, Olivier KR, Lynch JW Jr, Mendenhall NP: Lethal midline granuloma-nasal natural killer/T-cell lymphoma. Am J Clin Oncol; 2006 Apr;29(2):202-6
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for lethal midline granuloma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lethal midline granuloma-nasal natural killer/T-cell lymphoma.
  • PURPOSE: The purpose of this paper is to discuss lethal midline granuloma (LMG)-nasal natural killer (NK) T-cell lymphoma (LMG-NTL).
  • RESULTS: LMG is a rare entity that usually arises in the nasal cavity, exhibits a male preponderance, and has a wide age range.
  • The optimal treatment of LMG-NTL is unclear and is most likely moderate-dose radiotherapy.
  • The prognosis for patients with LMG-NTL is significantly worse than for patients with other types of head and neck non-Hodgkin lymphomas (NHL).
  • Initial local-regional disease progression is the predominant pattern of treatment failure.
  • CONCLUSIONS: LMG-NTL is a rare nasal NK/T-cell lymphoma that can be difficult to distinguish from other benign and malignant entities.
  • The patterns of failure suggest a role for more aggressive local-regional treatment, as well as more effective chemotherapy.
  • [MeSH-major] Granuloma, Lethal Midline / pathology. Lymphoma, T-Cell / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Killer Cells, Natural. Neoplasm Staging. Prognosis. Sex Factors. Survival Analysis

  • Genetic Alliance. consumer health - Midline lethal granuloma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16601443.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


6. Loong S, Soong YL, Tham I, Lee KM: Primary nasal lymphoma, NK/T-cell type: report of two cases with similar presentation but different outcome. Australas Radiol; 2004 Mar;48(1):84-7
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary nasal lymphoma, NK/T-cell type: report of two cases with similar presentation but different outcome.
  • Two cases of natural killer (NK)/T-cell primary nasal lymphoma with similar clinical presentations are reported, for comparison and contrast, to highlight the clinical issues and challenges posed by this unusual disease, its aggressiveness being matched only by its rarity.
  • Presenting as a lesion in the nasal cavity with histological features of malignant lymphoma, primary nasal lymphoma is an uncommon extranodal lymphoma, which poses problems in both diagnosis and management.
  • In people of oriental descent, the common cell subtype is NK/T-cell.
  • Although it is generally thought that combination treatment with chemotherapy and radiation is the best management for early stage non-Hodgkin's lymphoma (NHL), there is still debate as to whether combined therapy is optimal treatment for this particular subtype of NHL, given that it responds less well to conventional chemotherapy.
  • [MeSH-major] Killer Cells, Natural. Lymphoma, T-Cell / diagnosis. Nasal Septum. Nose Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Male. Prognosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15027930.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


7. Zeglaoui I, Belcadhi M, Sriha B, Bouzouita K: Nasal NK/T-cell lymphoma in the paediatric population. Two case reports. B-ENT; 2009;5(2):119-23
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal NK/T-cell lymphoma in the paediatric population. Two case reports.
  • Nasal natural killer (NK)/T-cell lymphoma is an uncommon disease, and only a few paediatric cases are found in the literature.
  • We report 2 cases of NK/T-cell lymphoma occurring in children.
  • The primary site was the the nasal cavity in the first case (5-year-old girl) and the tonsil in the second case (4-year-old boy).
  • Histological study showed a polymorphic neoplastic infiltrate with an angioinvasive pattern and T-cell phenotype.
  • Both underwent an aggressive chemotherapy regimen.
  • The outcome was favorable for the 4-year old boy; however, the 5-year-old girl died two months after diagnosis.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy. Tonsillar Neoplasms / diagnosis. Tonsillar Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670600.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


8. Wang H, Li XJ, Zhang SW, Xi Y: [Clinical study of extranodal NK-T cell lymphoma-nasal type]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Nov;40(11):850-4
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of extranodal NK-T cell lymphoma-nasal type].
  • OBJECTIVE: To discuss how the diagnosis, misdiagnosis and different treatment modalities affect the prognosis of the patients with extranodal NK-T cell lymphoma-nasal type.
  • METHODS: A retrospective study was made on the clinical characteristics, treatment modality, short-term effect, and survival rate of 68 patients with extranodal NK-T cell lymphoma-nasal type.
  • Among them,60 patients staged I(E) were subdivided into single therapy group of 20 cases( radiation therapy 9 cases, chemotherapy 11 cases) and combined therapy group of 40 cases (9 cases with radiation therapy + chemotherapy, 12 cases with chemotherapy + radiation therapy,19 cases with chemotherapy + radiation therapy + chemotherapy).
  • Eight patients staged IV(E) included 3 cases with radiation therapy alone and 5 cases with chemotherapy and radiation therapy.
  • 9% (36/68). The CR rate of radiation therapy was 94.
  • 4% (17/18) for limited disease in I(E) group compared 61.9% (26/42) for out-cavity disease in I(E) group, of which the difference is significant (P =0. 012).
  • The 1-years, 3-years and 5-years survival rate of the I(E) intra-cavity group were 100%, 77.8%, 59.8%, and those of ex-cavity group were 80.1%, 48.5% and 14.6%, respectively.
  • The 1, 3, 5-years survival rate of 60 I(E) patients with single therapy were 68.4%, 22.8% and 7.6% respectively; and that of combined therapy group were 94.9%, 81.1% and 52.4% respectively, which was significant difference (P = 0. 000).
  • The survival difference among the radiation therapy + chemotherapy group, chemotherapy + radiation therapy group and chemotherapy + radiation therapy + chemotherapy group were not significant (P = 0.088).
  • CONCLUSIONS: The early clinical manifestation of extranodal NK-T cell lymphoma-nasal type is not typical,which is easy to be misdiagnosed and mistreated.
  • Early therapy is the key,which can achieve good location control.
  • Diseased stage I(E) out-cavity and above should be treated with combined therapy.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell. Nose Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16408753.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Ren X, Jia Q, Xiang G, Zhao Z, Xu K, Du W: [Clinical study of 34 patients with extranodal NK/T cell lymphoma-nasal type]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Apr;21(8):361-2
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of 34 patients with extranodal NK/T cell lymphoma-nasal type].
  • OBJECTIVE: To explore the clinical feature, the reason of misdiagnosis and mistreatment, influential factor of prognosis in patients with extranodal NK/T cell lymphoma-nasal type.
  • METHOD: A retrospective study was made on the clinical data of 34 patients with extranodal NK/T cell lymphoma-nasal type.
  • Among them, 10 cases were staged I(E) intra-cavity, 15 cases were I(E) ex-cavity, 6 cases were II(E) and 3 cases were IV(E).
  • Among them, 29 cases were in nasal cavity, 5 cases were outside nasal cavity; 14 cases were treated with single chemotherapy or radiation therapy, 20 cases were treated with radiation therapy add chemotherapy.
  • The 5-year survival rate of the I(E) intra-cavity group were 60.0% (6/10), and those of I(E) ex-cavity group were 26.7% (4/15), and those of II(E) group and IV(E) group were 16.7% (1/6), 0% (0/3), respectively There was significant difference between 3 groups by statistical analysis (P < 0.01).
  • The 5-year survival rate of I(E) ex-cavity group treated with single therapy were 0% (0/6), and those of I(E)-cavity group treated with combined therapy were 50% (1/2).
  • CONCLUSION: The early clinical manifestation of extranodal NK/T tell lymphoma-nasal type is atypical and which is hard to diagnose and treat.
  • Diagnosis depends on pathologic biopsy and immunohistochemistry, there are many factors that influence the prognosis of this disease, in which the clinical stage is a major factor.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell. Nose Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608157.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Takahashi N, Miura I, Chubachi A, Miura AB, Nakamura S: A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma. Int J Hematol; 2001 Oct;74(3):303-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma.
  • We describe the clinicopathological features of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome (T/NK-LAHS).
  • Group 1 developed HPS during the clinical course, typically at the terminal phase of the disease.
  • This group consisted of 7 patients with extranodal lymphoma arising in the nasal cavity, paranasal cavity, tonsils, or skin at presentation.
  • In 5 of these patients, the preferred diagnosis was nasal and nasal-type NK/T-cell lymphoma, whereas the disease diagnoses in the remaining 2 patients were peripheral T-cell lymphoma of unspecified type and angioimmunoblastic T-cell lymphoma, respectively.
  • Group 2 consisted of 13 patients whose disease corresponded to so-called malignant histiocytosis-like lymphoma, which is characterized by HPS at the initial presentation and the infiltration of the liver, spleen, and/or bone marrow without tumor formation.
  • Nine of these 13 cases were found to have common histopathological features: CD56+, Epstein-Barr virus positivity, cytotoxic molecules, and nasal-type NK/T-cell lymphoma.
  • The very poor prognosis of T/NK-LAHS may be partly explained by the finding that nasal and nasal-type NK/T-cell lymphoma, which is resistant to standard chemotherapy, made up the highest percentage (70%) of the cases.
  • [MeSH-major] Histiocytosis, Non-Langerhans-Cell / pathology. Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology. Nose Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Rinsho Ketsueki. 1994 Sep;35(9):837-45 [7967052.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1184-200 [10524519.001]
  • [Cites] Cancer. 1986 Jul 1;58(1):67-71 [2423228.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):909-16 [8101471.001]
  • [Cites] Leuk Lymphoma. 1995 Nov;19(5-6):401-6 [8590839.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):666-70 [7884427.001]
  • [Cites] Rinsho Ketsueki. 1994 Jan;35(1):75-9 [8139105.001]
  • [Cites] Hematol Oncol. 1992 Sep-Oct;10(5):261-71 [1493910.001]
  • [Cites] Arch Pathol Lab Med. 1992 Nov;116(11):1209-12 [1332644.001]
  • [Cites] Am J Med. 1983 Nov;75(5):741-9 [6638043.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Blood. 1990 Jan 15;75(2):434-44 [2153036.001]
  • [Cites] Am J Hematol. 1991 Dec;38(4):321-3 [1746541.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S8-12 [9894466.001]
  • [Cites] Pathology. 1989 Apr;21(2):154-5 [2812878.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1474-83 [8608238.001]
  • [Cites] Hematol Oncol. 1989 Jul-Aug;7(4):275-85 [2786835.001]
  • [Cites] Br J Haematol. 1994 Jul;87(3):535-43 [7993793.001]
  • [Cites] Blood. 1992 May 1;79(9):2432-7 [1373974.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]
  • (PMID = 11721967.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / RNA, Viral
  •  go-up   go-down


11. Sakamoto M, Miyairi Y, Ishizawa M: Optimal specimen site for diagnosis of nasal T/NK cell lymphoma and treatment including bone marrow transplantation. ORL J Otorhinolaryngol Relat Spec; 2003 Sep-Oct;65(5):275-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal specimen site for diagnosis of nasal T/NK cell lymphoma and treatment including bone marrow transplantation.
  • Nasal T/NK cell lymphoma is characterized by unrelenting progressive ulceration and necrosis of the nasal cavity and midline facial tissues.
  • Computer tomography scans and biopsy specimens from 4 cases were studied in order to determine the optimal sampling site.
  • Specimens should be from the lateral plate of the nasal cavity and the inferior turbinate.
  • Bone marrow transplantation was performed in 2 cases following chemotherapy and radiotherapy.
  • The combination of chemotherapy, radiotherapy, and bone marrow transplantation has some ability to control the disease.
  • [MeSH-major] Bone Marrow Transplantation. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Fine-Needle. Chemotherapy, Adjuvant / methods. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Female. Humans. Male. Prednisone / administration & dosage. Radiotherapy, Adjuvant / methods. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14730183.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol, modified
  •  go-up   go-down


12. Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH, Park KW, Kang JH, Park JO, Lee SH, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Ko YH, Ahn YC, Park K: Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer; 2005 Jul;41(10):1402-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.
  • The purpose of this study was to define distinctive clinical features of "nasal" and "nasal-type" NK/T cell lymphomas by assessing prognostic factors.
  • The anatomic definition of extranasal NK/T cell lymphoma has been vague resulting in variable definitions of extranasal sites by different groups.
  • We analysed the clinical behavior of 90 NK/T cell lymphoma patients and attempted to elucidate the prognostic factors for risk-based stratification of therapy.
  • We observed no significant difference between "nasal" and "nasal-type" NK/T cell lymphomas in regards to clinical features and survival using the conventional anatomic classification.
  • We suggest the categorisation of the two subtypes of NK/T cell lymphoma as follows: UNKTL (upper aerodigestive tract NK/T cell lymphoma) including all lymphomas confined to nasal cavity, nasopharynx, and the upper aerodigestive tract and EUNKTL (extra-upper aerodigestive tract NK/T cell lymphoma) group to include all sites other than the UNKTL group.
  • The EUNKTL group in this study had advanced stage at diagnosis, higher LDH, higher IPI score, poorer performance and inferior response to the anthracycline-based chemotherapy with statistical significance.
  • More aggressive treatment should be sought for this particular group of patients for EUNKTL patients.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Assessment. Risk Factors. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15963893.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Oshimi K: NK cell lymphoma. Int J Hematol; 2002 Aug;76 Suppl 2:118-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK cell lymphoma.
  • Natural killer (NK) cells are lymphocytes with large granular lymphocyte morphology, CD3-CD56+ phenotype, non-MHC-restricted cytotoxicity, and germ-line configuration T-cell receptor genes.
  • Two types of lymphomas originating from NK cells have been described; blastic NK-cell lymphoma, and nasal-type NK-cell lymphoma.
  • Because recent reports indicate that blastic NK-cell lymphoma originates from the precursors of plasmacytoid dendritic cells, I will focus mainly on nasal-type NK-cell lymphoma, and discuss its pathogenesis, diagnostic problems, treatment strategy, and outcome.
  • Nasal-type NK-cell lymphoma develops mostly in the nasal cavity and rarely in other sites, such as the skin and intestinal tract.
  • Epstein-Barr virus (EBV) is found in lymphoma cells of almost all the patients, and is considered to be the etiologic agent.
  • Indeed, EBV easily infects NK cells in the absence of CD21 antigen, or EBV receptor, on the surface of NK cells.
  • Further, various types of oncogenes and suppressor oncogenes are found to be involved in its pathogenesis.
  • Based on the data obtained from paraffin-embedded specimens, it is difficult to determine whether the lymphoma cells are of T-cell or NK-cell lineage, because immunohistochemical staining of cytoplasmic CD3 is positive both in T and NK cells, and CD56 is positive in a part of T cells.
  • The presence of CD5 antigen indicates T-cell lineage.
  • When the disease is limited, radiation therapy is effective, but not satisfactory.
  • A new trial to use simultaneously both radiation and chemotherapy has started in Japan.
  • In advanced stages, a combination chemotherapy including L-asparaginase seems to be promising, and high-dose chemotherapy with autologous or allogeneic stem cell support is under investigation.
  • A recent report described the expression of short-length P-glycoprotein (P-gp), but not full-length P-gp in NK cells, and this mini-P-gp is unable to extrude daunorubicin.
  • These findings may change the treatment strategy.
  • Finally, I will present the results on interim analysis of 166 cases of nasal-type NK-cell lymphoma collected in Japan between 1994 and 1998.
  • [MeSH-major] Killer Cells, Natural. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans. Nose Neoplasms / diagnosis. Nose Neoplasms / etiology. Nose Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1999 Nov;155(5):1419-25 [10550295.001]
  • [Cites] Blood. 2001 May 15;97(10):3210-7 [11342451.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):54-63 [10623693.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1556-63 [11861268.001]
  • [Cites] Br J Haematol. 2001 Jul;114(1):177-84 [11472365.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):225-8 [11722437.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):666-70 [7884427.001]
  • [Cites] Immunol Today. 1988 Oct;9(10):291-3 [2978371.001]
  • [Cites] Br J Haematol. 1990 May;75(1):49-59 [2375924.001]
  • [Cites] Int J Hematol. 2001 Dec;74(4):447-50 [11794702.001]
  • [Cites] Radiology. 1997 Aug;204(2):467-70 [9240537.001]
  • [Cites] Leuk Lymphoma. 1999 Jul;34(3-4):241-50 [10439361.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1803-9 [11106552.001]
  • [Cites] Adv Immunol. 1989;47:187-376 [2683611.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1474-83 [8608238.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1466-73 [8608237.001]
  • [Cites] Jpn J Cancer Res. 2001 Oct;92(10):1048-56 [11676855.001]
  • [Cites] Leuk Res. 1999 Jul;23(7):615-24 [10400182.001]
  • [Cites] Lab Invest. 2000 Apr;80(4):493-9 [10780666.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):449-56 [9690537.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]
  • [Cites] Immunol Rev. 1998 Oct;165:75-86 [9850853.001]
  • (PMID = 12430911.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 23
  •  go-up   go-down


14. Sawada M, Yamada T, Tsurumi H, Moriwaki H: [Nasal NK cell lymphoma with hemophagocytic syndrome developed tumor lysis syndrome after CHOP therapy]. Rinsho Ketsueki; 2002 Nov;43(11):988-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nasal NK cell lymphoma with hemophagocytic syndrome developed tumor lysis syndrome after CHOP therapy].
  • A bulky mass was observed in his left nasal cavity.
  • A diagnosis of nasal NK cell lymphoma with hemophagocytic syndrome (clinical stage IVB) was made.
  • Following CHOP regimen chemotherapy, the tumor transiently reduced in size, but the patient developed multiple organ failure possibly due to tumor lysis syndrome.
  • His general condition was improved by intensive supporting therapy.
  • Despite salvage chemotherapy with a P-IMVP16/CBDCA regimen, the patient died of multiple organ failure due to tumor lysis syndrome.
  • Autopsy revealed diffuse necrosis and fibrosis without proliferation of lymphoma cells in the liver, spleen, bone marrow, and lymph nodes.
  • The poor prognosis of NK/T cell lymphoma might be associated with massive tissue damage with hypercytokinemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cyclophosphamide / adverse effects. Doxorubicin / adverse effects. Histiocytosis, Non-Langerhans-Cell / etiology. Killer Cells, Natural. Lymphoma, T-Cell / drug therapy. Nose Neoplasms / drug therapy. Prednisone / adverse effects. Tumor Lysis Syndrome / etiology. Vincristine / adverse effects
  • [MeSH-minor] Adult. Humans. Male. Multiple Organ Failure / etiology. Nasal Cavity / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12508484.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Lee JY, Jang YD, Kim HK: The primary role of the otolaryngologist in managing pediatric sinonasal malignancies: an extranodal NK/T-cell lymphoma originating from the inferior turbinate mucosa of the nasal cavity. J Pediatr Hematol Oncol; 2008 May;30(5):401-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The primary role of the otolaryngologist in managing pediatric sinonasal malignancies: an extranodal NK/T-cell lymphoma originating from the inferior turbinate mucosa of the nasal cavity.
  • The primary role of the otolaryngologist in managing patients with a sinonasal malignancy is to make an early diagnosis.
  • Recently, we observed a nasal extranodal natural killer/T-cell lymphoma in a 12-year-old girl with a 6-month history of right nasal obstruction.
  • Her symptom worsened gradually despite medical treatment at a private hospital.
  • The histopathology and immunohistochemical staining of a punch biopsy confirmed the diagnosis.
  • In this case, we emphasize the importance of a complete endoscopic examination of the nasal cavity in a pediatric patient with unilateral nasal symptoms and the possible necessity of referral to an otolaryngologist to prevent misdiagnosis and management of the pathology as benign.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy. Nasal Mucosa / pathology. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Otolaryngology / methods. Prednisone / administration & dosage. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458579.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


16. Berk V, Yildiz R, Akdemir UO, Akyurek N, Karabacak NI, Coskun U, Benekli M: Disseminated extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous nodules: utility of 18F-FDG PET in staging. Clin Nucl Med; 2008 May;33(5):365-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous nodules: utility of 18F-FDG PET in staging.
  • A 49-year-old man presented with a left nasal cavity mass, biopsy of which revealed extranodal NK/T cell lymphoma.
  • A PET-CT scan showed increased F-18 FDG uptake in the nasal mass, anterior mediastinal lymph nodes, and multiple subcutaneous nodular deposits in the chest wall, gluteal region, and right femoral areas.
  • The patient achieved complete remission with salvage l-asparaginase therapy after failing first-line standard anthracycline-based chemotherapy.
  • There is limited literature data on the use of the PET scan in the diagnosis and staging of extranodal nasal NK/T-cell lymphomas.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Extranodal NK-T-Cell / radionuclide imaging. Nose Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Skin Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431160.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Pagano L, Gallamini A, Trapè G, Fianchi L, Mattei D, Todeschini G, Spadea A, Cinieri S, Iannitto E, Martelli M, Nosari A, Bona ED, Tosti ME, Petti MC, Falcucci P, Montanaro M, Pulsoni A, Larocca LM, Leone G, Intergruppo Italiano Linfomi: NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey. Ann Oncol; 2006 May;17(5):794-800
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey.
  • OBJECTIVE: To evaluate the clinical characteristics and outcome of NK/T-cell lymphoma 'nasal type' developed in Italian patients.
  • PATIENTS: Between 1997 and 2004, 26 new cases of NK/T-cell lymphoma 'nasal type' were diagnosed in 10 Italian Hematology institutions.
  • In 23 cases presentation at the onset was in the nasal cavity or adjacent structures, in two cases the lymphoma onset with skin lesions was followed successively by rhynopharyngeal dissemination, while the remaining case had bone marrow and lymph node involvement followed by oro-pharyngeal involvement.
  • Diagnosis was based on the finding of a NK/T-cell phenotype at the histological and immunophenotypic examination of oropharyngeal or cutaneous lesions.
  • All patients but one were treated with chemotherapy, alone in nine cases or associated to radiotherapy in 14 cases; two patients had chemotherapy, radiotherapy and surgery, while one patient underwent only surgery.
  • Chemotherapy was anthracycline-based in 17 out of 25 cases.
  • In those patients in whom radiotherapy was performed, radiation dosages ranged between 36 Gy and 47.5 Gy, with a median dosage of 40 Gy.
  • Nine patients (34%) were responsive to the treatments: six patients obtained a complete remission and other three a partial remission.
  • The remaining 17 patients resulted refractory or presented a limited response to therapy.
  • The median disease-free survival was 14 months and the median overall survival time was 9 months.
  • CONCLUSION: The results of this retrospective survey confirmed that NK/T-cell lymphoma 'nasal type' is a very rare lymphoma in the Italian population, and it is characterized by a very bad prognosis.
  • Due to the rarity of this disease, a standardized therapeutic approach is lacking.
  • More data are needed to know the epidemiology of this kind of lymphoma in Europe.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497823.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Yang C, Ma J, Yang X, Jia L, Liu H, Xiao J: Natural killer/T-cell nasal-type lymphoma: unusual primary spinal tumor. Spine (Phila Pa 1976); 2008 Nov 15;33(24):E929-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer/T-cell nasal-type lymphoma: unusual primary spinal tumor.
  • STUDY DESIGN: A natural killer/T-cell lymphoma originating in the spine of a 60-year-old man is first reported, along with a brief review of the literature on the topic.
  • OBJECTIVE: To describe the presentation and diagnosis of this disorder along with an emphasis on the importance of this type of rare tumor, needing early and accurate immunophenotypic profiling to make a right diagnosis.
  • SUMMARY OF BACKGROUND DATA: Natural killer (NK)/T-cell lymphomas represent a rare type of lymphoma derived from either activated NK cell or rarely cytotoxic T cells.
  • It usually originates in the nasal cavity/nasopharynx and invades the surrounding tissues, which is aggressive and, usually, a delay in diagnosis could result in a fatal outcome.
  • METHODS: A 60-year-old man presented with severe pain in his chest and back for 3 weeks and developed paralysis soon.
  • The histopathology was consistent with NK/T-cell lymphomas.
  • He was not suitable for any aggressive chemotherapy or radiation therapy because of his poor condition and died 20 days later.
  • CONCLUSION: NK/T-cell lymphomas originated at other sites but nasal cavity/nasopharynx do not present typical clinical features and symptoms in the absence of lymphadenopathy.
  • There are possibilities for misdiagnosis of NK/T-cell lymphoma that originates at other sites.
  • The unfavorable prognosis of this tumor emphasized the need for novel molecular targets and more effective therapies.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell, Peripheral / pathology. Spinal Neoplasms / pathology. T-Lymphocytes, Cytotoxic / pathology. Thoracic Vertebrae / pathology
  • [MeSH-minor] Back Pain / etiology. Back Pain / pathology. Chest Pain / etiology. Chest Pain / pathology. Fatal Outcome. Humans. Immunophenotyping. Joint Instability / etiology. Joint Instability / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Multiple Organ Failure / etiology. Multiple Organ Failure / pathology. Paralysis / etiology. Severity of Illness Index. Spinal Cord Compression / etiology. Spinal Cord Compression / pathology. Spinal Fractures / etiology. Spinal Fractures / pathology. Spinal Fusion. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011534.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


19. Guo Y, Lu JJ, Ma X, Wang B, Hong X, Li X, Li J: Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Oral Oncol; 2008 Jan;44(1):23-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
  • The objective of this analysis was to evaluate the efficacy and treatment outcome of CHOP and CHOP combined with nitrosourea chemotherapy in natural killer (NK)/T-cell lymphoma of the nasal cavity.
  • Sixty-three patients with NK/T-cell lymphoma of the nasal cavity were treated with CHOP or CHOP combined with oral nitrosourea chemotherapy between January 1997 and June 2005.
  • By the Ann Arbor Lymphoma Staging Classification, 57 patients (90%) had Stage IE or IIE disease and six patients (10%) had Stage III or IV disease.
  • All patients with Stage IE or IIE disease were intended to be treated curatively with combined chemoradiation; and patients who had Stage III or IV disease were treated with chemotherapy alone with curative intention.
  • Chemotherapy consisted of:.
  • (1) up to six cycles of the standard CHOP based regimen, or (2) up to six cycles of the standard CHOP based regimen with oral Semustine dosed at 120 mg (or Lomustine dosed at 100mg) on day 1 of each chemotherapy cycle.
  • External beam radiation therapy was delivered by daily conventional fractionation by Co-60 or 6MVx linear accelerator for patients with Stage IE or IIE disease.
  • The radiation dose to the tumor bed was between 36 and 50 Gy with a median dose of 45 Gy.
  • Fifty-three patients received chemotherapy prior to radiation, and four patients were treated with involved field radiation before chemotherapy.
  • Nine patients with Stage IE or IIE diseases developed disease progression during their planned treatment and died within 10 months after the initiation of treatment; Six patients who achieved complete response (CR) after planned chemoradiation developed systemic recurrence and died at 13-48 months despite salvage treatment; one patient died of Hemophagocytic Syndrome during radiotherapy after achieving CR from chemotherapy.
  • Three patients with Stage III or IV disease died during chemotherapy or during salvage treatment at 2, 4, and 19 months, respectively.
  • Among the 59 patients who received chemotherapy as their initial treatment, 29, 6, 12, and 12 patients had complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) respectively after chemotherapy.
  • Multivariate analysis revealed that International Prognostic Index (IPI) for Lymphoma, perforation of nasal septum as a presenting symptom, "B" symptoms, ECOG performance, as well as response after chemotherapy, were significant independent prognostic factors for this group of patients.
  • The extent of response after induction chemotherapy is significantly related to the treatment outcome of patients with nasal NK/T-cell lymphoma.
  • CHOP based chemotherapy combined with oral nitrosourea followed by involved field radiotherapy may provide improved treatment results compared to conventional CHOP chemotherapy and radiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Extranodal NK-T-Cell / drug therapy. Nose Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Lomustine / administration & dosage. Male. Middle Aged. Retrospective Studies. Semustine / administration & dosage. Survival Rate

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Semustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306611.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 13909-09-6 / Semustine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


20. Kato T, Tanabe J, Kanemoto M, Kobayashi C, Morita S, Karahashi T: A case of extranodal NK/T-cell lymphoma, nasal type mimicking typical manifestations of adult-onset Still's disease (AOSD) with hemophagocytic syndrome: diagnostic consideration between malignant lymphoma without lymphadenopathy and AOSD. Mod Rheumatol; 2009;19(6):675-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of extranodal NK/T-cell lymphoma, nasal type mimicking typical manifestations of adult-onset Still's disease (AOSD) with hemophagocytic syndrome: diagnostic consideration between malignant lymphoma without lymphadenopathy and AOSD.
  • Therefore, the possibility of malignant lymphoma was considered to be extremely low.
  • Leukocytopenia (2.4 x 10(3)/mul) was observed, and thus a diagnosis of adult-onset Still's disease (AOSD) with hemophagocytic syndrome (HPS) was made.
  • Bone marrow aspiration revealed the presence of lymphoma cells and hemophagocytosis, and the CD45 gating analysis showed expanding population of CD2(+), CD3(-), and CD56(+) cells.
  • Further, mucosal ulceration in the nasal cavity was detected.
  • Therefore, a diagnosis of extranodal natural killer (NK)/T-cell lymphoma, nasal type, concomitant with HPS was made, and treatment with dexamethasone, etoposide, ifosfamide, carboplatin (DeVIC) regimen ameliorated his symptoms and platelet transfusion dependency.
  • Later, a high titer of serum EBV-DNA was detected, which supported the diagnosis.
  • Diagnosing AOSD, extranodal presentation of malignant lymphoma such as extranodal NK/T-cell lymphoma, nasal type, should be carefully considered.

  • Genetic Alliance. consumer health - Still's disease adult onset.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609486.001).
  • [ISSN] 1439-7609
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


21. Karaman E, Yilmaz M, Alimoglu Y, Edizer DT, Isildak H, Ozek H: Extranodal sinonasal natural killer/T-cell lymphoma presenting as chronic sinusitis and necrotic wound infection. J Craniofac Surg; 2009 Nov;20(6):2095-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal sinonasal natural killer/T-cell lymphoma presenting as chronic sinusitis and necrotic wound infection.
  • Necrotic lesion then extended to the nasal cavity and skin of the face.
  • The biopsy revealed natural killer/T-cell lymphoma.
  • The patient was treated with chemotherapy; however, the patient died owing to sepsis.
  • Sinonasal lymphoma is a rare disease.
  • It is managed with chemotherapy and radiotherapy.
  • A high index of clinical suspicion is required for early diagnosis.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Female. Humans. Maxillary Sinusitis / diagnosis. Maxillary Sinusitis / surgery. Necrosis. Wound Infection / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881363.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Chen CS, Miller NR, Lane A, Eberhart C: Third cranial nerve palsy caused by intracranial extension of a sino-orbital natural killer T-cell lymphoma. J Neuroophthalmol; 2008 Mar;28(1):31-5
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Third cranial nerve palsy caused by intracranial extension of a sino-orbital natural killer T-cell lymphoma.
  • Natural killer/T-cell lymphomas (NKTLs) are rare destructive lesions that usually involve the nasal cavity or paranasal sinuses.
  • A 53-year-old man with systemic lupus erythematosus who was receiving chronic low-dose prednisone treatment developed proptosis of the right eye.
  • Clinical and imaging manifestations resolved with a higher dose of prednisone, but when the prednisone dose was tapered, the patient developed a complete right third cranial nerve palsy.
  • Biopsy of this lesion in its early stage may misleadingly suggest a primary inflammatory disorder because of a paucity of neoplastic cells, a large number of inflammatory cells recruited by the innate natural killer (NK) cell immune response, and extensive necrosis caused by angiodestructive tumor cells.
  • [MeSH-major] Frontal Lobe / pathology. Lymphoma, Extranodal NK-T-Cell / complications. Lymphoma, Extranodal NK-T-Cell / diagnosis. Oculomotor Nerve Diseases / etiology. Oculomotor Nerve Diseases / pathology. Orbit / pathology. Paranasal Sinuses / pathology
  • [MeSH-minor] Antigens, Neoplasm / analysis. Antigens, Neoplasm / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / immunology. Fatal Outcome. Humans. Immunosuppressive Agents / therapeutic use. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Oculomotor Nerve / pathology. Oculomotor Nerve / physiopathology. Prednisone / therapeutic use. Radiotherapy. Tomography, X-Ray Computed. Treatment Failure

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347456.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Immunosuppressive Agents; VB0R961HZT / Prednisone
  •  go-up   go-down


23. Cheung MM, Chan JK, Wong KF: Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol; 2003 Jul;40(3):221-32
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias.
  • Natural killer (NK) cell neoplasms, which include extranodal NK/T-cell lymphoma (nasal and extranasal) and aggressive NK cell leukemia, are generally rare, but they are more common in people of Oriental, Mexican and South American descent.
  • Extranodal NK/T-cell lymphoma most commonly affects the nasal cavity and other mucosal sites of the upper aerodigestive tract.
  • Patients present with nasal obstruction or midfacial destruction.
  • Patients with the extranasal form of the lymphoma often present with high-stage disease, commonly involving the skin, gastrointestinal tract, testis, and soft tissue, and the prognosis is even worse.
  • Histologically, the lymphoma can show a broad cytologic spectrum, but apoptosis, necrosis, and angioinvasion are common.
  • Based on currently available data, treatment of nasal NK/T-cell lymphoma should consist of radiotherapy, with or without multiagent chemotherapy.
  • More research is required to ascertain the role of high-dose chemotherapy with stem cell rescue and that of non-multidrug resistance-related chemotherapeutic agents.
  • Aggressive NK cell leukemia affects younger patients, who present with poor general condition, fever, and disseminated disease; they often die within a short time from systemic disease or complications such as multi-organ failure.
  • The peripheral blood and bone marrow show atypical large granular lymphocytes, which exhibit an immunophenotype similar to that of extranodal NK/T-cell lymphoma.
  • Aggressive NK cell leukemia must be distinguished from T-cell large granular lymphocyte leukemia and indolent NK cell lymphoproliferative disorder, both of which are indolent.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia / pathology. Lymphoma / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12876671.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


24. Li LL, Liu HG, Piao YS, He CY, Zhou Q, Zhang Y: [Clinicopathologic study of malignant tumors in head and neck region complicated by fungal infection]. Zhonghua Bing Li Xue Za Zhi; 2010 Aug;39(8):508-12
MedlinePlus Health Information. consumer health - Sinusitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These patients had history of chemotherapy/radiotherapy or antibiotics usage.
  • The remaining 13 cases of fungal infection often affected necrotic tumor tissue in nasal cavity, paranasal sinuses, pharynx, larynx and palate.
  • On the other hand, Aspergillus and Candida are the commonest fungi found in the necrotic tumor tissue.
  • Pathologic examination remains the hallmark in confirming the diagnosis and fungal typing.
  • [MeSH-minor] Adolescent. Adult. Aged. Antifungal Agents / therapeutic use. Aspergillosis / drug therapy. Aspergillosis / microbiology. Aspergillosis / pathology. Aspergillus / isolation & purification. Candida / isolation & purification. Candidiasis / drug therapy. Candidiasis / microbiology. Candidiasis / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / microbiology. Carcinoma, Squamous Cell / pathology. Child. Female. Follow-Up Studies. Humans. Lymphoma, Extranodal NK-T-Cell / drug therapy. Lymphoma, Extranodal NK-T-Cell / microbiology. Lymphoma, Extranodal NK-T-Cell / pathology. Male. Middle Aged. Retrospective Studies. Young Adult. Zygomycosis / drug therapy. Zygomycosis / microbiology. Zygomycosis / pathology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21055027.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down






Advertisement